Publication: A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial
Issued Date
2020-01-01
Resource Type
ISSN
14320428
0012186X
0012186X
Other identifier(s)
2-s2.0-85077686072
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diabetologia. (2020)
Suggested Citation
Arun Nanditha, Hazel Thomson, Priscilla Susairaj, Weerachai Srivanichakorn, Nick Oliver, Ian F. Godsland, Azeem Majeed, Ara Darzi, Krishnamoorthy Satheesh, Mary Simon, Arun Raghavan, Ramachandran Vinitha, Chamukuttan Snehalatha, Kate Westgate, Soren Brage, Stephen J. Sharp, Nicholas J. Wareham, Desmond G. Johnston, Ambady Ramachandran A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial. Diabetologia. (2020). doi:10.1007/s00125-019-05061-y Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/49668
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial
Author(s)
Arun Nanditha
Hazel Thomson
Priscilla Susairaj
Weerachai Srivanichakorn
Nick Oliver
Ian F. Godsland
Azeem Majeed
Ara Darzi
Krishnamoorthy Satheesh
Mary Simon
Arun Raghavan
Ramachandran Vinitha
Chamukuttan Snehalatha
Kate Westgate
Soren Brage
Stephen J. Sharp
Nicholas J. Wareham
Desmond G. Johnston
Ambady Ramachandran
Hazel Thomson
Priscilla Susairaj
Weerachai Srivanichakorn
Nick Oliver
Ian F. Godsland
Azeem Majeed
Ara Darzi
Krishnamoorthy Satheesh
Mary Simon
Arun Raghavan
Ramachandran Vinitha
Chamukuttan Snehalatha
Kate Westgate
Soren Brage
Stephen J. Sharp
Nicholas J. Wareham
Desmond G. Johnston
Ambady Ramachandran
Abstract
© 2020, The Author(s). Aims/hypothesis: This randomised controlled trial was performed in India and the UK in people with prediabetes to study whether mobile phone short message service (SMS) text messages can be used to motivate and educate people to follow lifestyle modifications, to prevent type 2 diabetes. Methods: The study was performed in people with prediabetes (n = 2062; control: n = 1031; intervention: n = 1031) defined by HbA1c ≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4%). Participants were recruited from public and private sector organisations in India (men and women aged 35–55 years) and by the National Health Service (NHS) Health Checks programme in the UK (aged 40–74 years without pre-existing diabetes, cardiovascular disease or kidney disease). Allocation to the study groups was performed using a computer-generated sequence (1:1) in India and by stratified randomisation in permuted blocks in the UK. Investigators in both countries remained blinded throughout the study period. All participants received advice on a healthy lifestyle at baseline. The intervention group in addition received supportive text messages using mobile phone SMS messages 2–3 times per week. Participants were assessed at baseline and at 6, 12 and 24 months. The primary outcome was conversion to type 2 diabetes and secondary outcomes included anthropometry, biochemistry, dietary and physical activity changes, blood pressure and quality of life. Results: At the 2 year follow-up (n = 2062; control: n = 1031; intervention: n = 1031), in the intention-to-treat population the HR for development of type 2 diabetes calculated using a discrete-time proportional hazards model was 0.89 (95% CI 0.74, 1.07; p = 0.22). There were no significant differences in the secondary outcomes. Conclusions/interpretation: This trial in two countries with varied ethnic and cultural backgrounds showed no significant reduction in the progression to diabetes in 2 years by lifestyle modification using SMS messaging. Trial registration: The primary study was registered on www.ClinicalTrials.gov (India, NCT01570946; UK, NCT01795833). Funding: The study was funded jointly by the Indian Council for Medical Research and the UK Medical Research Council.